A Novel SCN9A Mutation (F826Y) in Primary Erythromelalgia Alters the Excitability of Nav1.7-Reference-Cited by-同舟云学术

A Novel SCN9A Mutation (F826Y) in Primary Erythromelalgia Alters the Excitability of Nav1.7

Published:2018-02-07 Issue:6 Volume:17 Page:
ISSN:1566-5240
Container-title:Current Molecular Medicine
language:en
Short-container-title:CMM

Author:

Wu B.¹,Zhang Y.²,Tang H.¹,Yang M.¹,Long H.³,Shi G.¹,Tang J.¹,Shi X.¹

Affiliation:

1. Department of Medical Genetics, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China

2. The National & Local Joint Engineering Laboratory of Animal Peptide Drug Development, College of Life Sciences, Hunan Normal University, Changsha 410081, Hunan, China

3. Department of Dermatology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China

Publisher

Bentham Science Publishers Ltd.

Subject

Molecular Biology,Molecular Medicine,General Medicine,Biochemistry

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hydropathicity-based prediction of pain-causing NaV1.7 variants;BMC Bioinformatics;2021-04-23

2. Engineering of highly potent and selective HNTX-III mutant against hNav1.7 sodium channel for treatment of pain;Journal of Biological Chemistry;2021-01

3. Painful and painless mutations of SCN9A and SCN11A voltage-gated sodium channels;Pflügers Archiv - European Journal of Physiology;2020-06-29

4. Voltage‐gated sodium channel 1.7 expression decreases in dorsal root ganglia in a spinal nerve ligation neuropathic pain model;The Kaohsiung Journal of Medical Sciences;2019-05-14

5. Discovery of a Novel Nav1.7 Inhibitor From Cyriopagopus albostriatus Venom With Potent Analgesic Efficacy;Frontiers in Pharmacology;2018-10-16